Code Pharma CEO Zyon Ayni has unveiled groundbreaking progress in the battle against HIV with the development of GAMMORA. Early results from phase 2 clinical trials show the drug’s potential to eliminate HIV-infected cells while leaving healthy cells unharmed—a major leap forward in HIV treatment.
“We have proven that HIV-infected cells can be eliminated,” says Ayni. With ongoing trials in multiple countries, GAMMORA could soon play a pivotal role in transforming HIV care. As the company moves toward larger trials and regulatory approval, Ayni’s vision for a potential cure is becoming a reality.
